China National Medical Products Administration

Company

Related News

Multiple Oncology Trials Report Positive Results at ASCO 2026 and in Journals

Jun 02, 2026

Multiple oncology trials present recent results, including cabozantinib-nivolumab activity in non-clear cell RCC, savolitinib efficacy in MET-amplified gastric cancer, and induction nivolumab feasibility in HPV-driven oropharyngeal cancer.

Cytokinetics Launches MYQORZO; C4 Therapeutics Advances Cemsidomide Trial

Feb 25, 2026

Cytokinetics launches MYQORZO for obstructive hypertrophic cardiomyopathy following FDA approval, while C4 Therapeutics doses first patient in Phase 2 trial of cemsidomide for relapsed/refractory multiple myeloma.